ASX Release – 24 May 2021

Filing of International Application under Patent Co-operation Treaty

For Method for Treating Viral, Inflammatory and Malignant Disease

Resonance Health Limited (ASX: RHT) ("Resonance Health" or "Company") advises that, further to its 'R&D Update' announcement on 17 May 2021, it has lodged an international application under the Patent Co-Operation Treaty ("PCT Patent Application") for the use of Antisense Oligonucleotides ("ASOs") to target a human gene associated with viral, inflammatory, and malignant disease.

The PCT Patent Application, which has been filed with IP Australia, seeks protection for a new method for treating viral, inflammatory, and malignant diseases. If granted, the PCT patent will have a term of 20 years from 19 May 2021. The list of states covered under the PCT is enclosed at Appendix A.

The filing of this PCT Patent Application is the culmination of extensive design, testing, and validation of multiple ASOs over the past twelve months by the Company's Molecular Medicine R&D team headed by Dr Sherif Boulos (see ASX announcement dated 17 May 2021).

The Company's ASO project initially investigated the application of specific compounds for use in modulation of Hepatitis B virus ("HBV"). In a preclinical cell model of HBV infection, the lead ASO ("AS3") demonstrated statistically significant viral suppression compared to a control ASO. Due to this promising data, a dosage study to test its effectiveness in a humanised liver mouse strain will soon commence. If successful, AS3's effectiveness in an HBV infection model using the same strain will then be assessed.

Chronic Hepatitis B is estimated to affect 292 million people globally, including an estimated 230,000 Australians. Current life-long treatments do not eliminate HBV, and up to 40% of sufferers will develop serious clinical complications such as cirrhosis, liver failure and/or liver cancer. Aside from the human suffering, the healthcare cost of chronic HBV in the USA is estimated to be USD$100K per patient per annum (U.S. Medicare figures, 2015; cited by Robert Gish MD, Medical Director of the Hepatitis B Foundation).

The filed international PCT Patent Application encompasses the Company's method for treatment for a number of drug target associated diseases in addition to HBV. Due to the Company's drug targets' implication in the progression of multiple diseases, and due to the potentially wide-ranging impact of the possible successful modulation of the Company's drug target by AS3 or other lead compounds developed by the Company, the expanded application and expansion of the project has been authorised by the Company's Board of Directors.

The ASO R&D project will now also investigate:

1. The use of AS3 as an antiviral treatment for patients co-infected with HBV and Hepatitis C Virus ("HCV") and/or Immunodeficiency Virus Type 1 ("HIV-1");

2. The use of AS3 for the treatment of serious inflammatory disorders, such as non-alcoholic fatty liver disease ("NAFLD") and in Hepatocellular carcinoma ("HCC"), wherein the drug's biological target has been found to be substantially expressed in patients with poor outcomes;

3. Evidence implicates a possible role for the Company's drug-target in the life cycle of Coronavirus strains, including those responsible for severe acute respiratory syndrome ("SARS") such as SARS-CoV-2, the causative agent of COVID-19. The Company will explore this further.

Chief Executive Officer, Alison Laws, says:

"Antisense therapies have interesting potential in application to various human diseases and conditions. Dr Boulos and his team are highly experienced designers and researchers, and although this work was initially targeting a particular liver disease, published research provides a body of evidence for the role of the Company's drug target across multiple diseases.

For Resonance Health, the possibility of developing effective therapies at relatively low R&D expenditure is interesting. Internationally, there have been a number of antisense oligonucleotide licencing deals over the last few years, demonstrating market validation of this type of investment. The Company intends to continue work on this project against controlled timelines and budgets and will provide further updates on the project as work progresses."

Authorised by:

This announcement has been authorised for release in accordance with the delegated authority of the Board of Directors of Resonance Health Limited.

For further information please contact:

Chad Tondut
Communications Manager, Resonance Health
E: chadt@resonancehealth.com P: +61 (0)8 9286 5300

Annex A

PCT Contracting States and Two-letter Codes (153 on 1 November 2020)



AE United Arab Emirates
AG Antigua and Barbuda
AL Albania (EP)
AM Armenia (EA)
AO Angola
AT Austria (EP)
AU Australia
AZ Azerbaijan (EA)
BA Bosnia and Herzegovina[1]
BB Barbados
BE Belgium (EP)[2]
BF Burkina Faso (OA)[2]
BG Bulgaria (EP)
BH Bahrain
BJ Benin (OA)[2]
BN Brunei Darussalam
BR Brazil
BW Botswana (AP)
BY Belarus (EA)
BZ Belize
CA Canada
CF Central African Republic (OA)[2]
CG Congo (OA)[2]
CH Switzerland (EP)
CI Côte d'Ivoire (OA)[2]
CL Chile
CM Cameroon (OA)[2]
CN China
CO Colombia
CR Costa Rica
CU Cuba
CY Cyprus (EP)[2]
CZ Czechia (EP)
DE Germany (EP)
DJ Djibouti
DK Denmark (EP)
DM Dominica
DO Dominican Republic
DZ Algeria
EC Ecuador
EE Estonia (EP)
EG Egypt
ES Spain (EP)
FI Finland (EP)
FR France (EP)[2]
GA Gabon (OA)[2]
GB United Kingdom (EP)
GD Grenada
GE Georgia
GH Ghana (AP)
GM Gambia (AP)
GN Guinea (OA)[2]
GQ Equatorial Guinea (OA)[2]
GR Greece (EP)[2]
GT Guatemala
GW Guinea-Bissau (OA)[2]
HN Honduras
HR Croatia (EP)
HU Hungary (EP)
ID Indonesia
IE Ireland (EP)[2]
IL Israel
IN India
IR Iran (Islamic Republic of)
IS Iceland (EP)
IT Italy (EP)[3]
JO Jordan
JP Japan
KE Kenya (AP)
KG Kyrgyzstan (EA)
KH Cambodia[4]
KM Comoros (OA)[2]
KN Saint Kitts and Nevis
KP Democratic People's Republic of Korea
KR Republic of Korea
KW Kuwait
KZ Kazakhstan (EA)
LA Lao People's Democratic Republic
LC Saint Lucia
LI Liechtenstein (EP)
LK Sri Lanka
LR Liberia (AP)
LS Lesotho (AP)
LT Lithuania (EP)[2]
LU Luxembourg (EP)
LV Latvia (EP)[2]
LY Libya
MA Morocco[4]
MC Monaco (EP)[2]
MD Republic of Moldova[4]
ME Montenegro[5]
MG Madagascar
MK North Macedonia (EP)
ML Mali (OA)[2]
MN Mongolia
MR Mauritania (OA)[2]
MT Malta (EP)[2]
MW Malawi (AP)
MX Mexico
MY Malaysia
MZ Mozambique (AP)
NA Namibia (AP)
NE Niger (OA)[2]
NG Nigeria
NI Nicaragua
NL Netherlands (EP)[2]
NO Norway (EP)
NZ New Zealand
OM Oman
PA Panama
PE Peru
PG Papua New Guinea
PH Philippines
PL Poland (EP)
PT Portugal (EP)
QA Qatar
RO Romania (EP)
RS Serbia (EP)
RU Russian Federation (EA)
RW Rwanda (AP)
SA Saudi Arabia
SC Seychelles
SD Sudan (AP)
SE Sweden (EP)
SG Singapore
SI Slovenia (EP)[2]
SK Slovakia (EP)
SL Sierra Leone (AP)
SM San Marino (EP)[2]
SN Senegal (OA)[2]
ST Sao Tome and Principe (AP)
SV El Salvador
SY Syrian Arab Republic
SZ Eswatini (AP)[2]
TD Chad (OA)[2]
TG Togo (OA)[2]
TH Thailand
TJ Tajikistan (EA)
TM Turkmenistan (EA)
TN Tunisia[4]
TR Turkey (EP)
TT Trinidad and Tobago
TZ United Republic of Tanzania (AP)
UA Ukraine
UG Uganda (AP)
US United States of America
UZ Uzbekistan
VC Saint Vincent and the Grenadines
VN Viet Nam
WS Samoa
ZA South Africa
ZM Zambia (AP)
ZW Zimbabwe (AP)

1 Extension of European patent possible.
2 May only be designated for a regional patent (the "national route" via the PCT has been closed).
3 Italy may be designated for a national patent only in international applications filed on or after 1 July 2020.
4 Validation of European patent possible.
5 Only extension of European patent possible. Applicants wishing to obtain patent protection in Montenegro should enter the regional phase before the European Patent Office (EPO) and seek the extension of the European patent application and the granted European patent to Montenegro as there is no national phase before the Intellectual Property Office of Montenegro.

Where a State can be designated for a regional patent, the two-letter code for the regional patent concerned is indicated in pa rentheses (AP = ARIPO patent, EA = Eurasian patent, EP = European patent, OA = OAPI patent).

Important: This list includes all States that have adhered to the PCT by the date shown in the heading. Any State indicated in ***bold italics*** has adhered to the PCT but will only become bound by the PCT on the date shown in parentheses; it will not be considered to have been designated in international applications filed before that date.

Note that even though the filing of a request constitutes under PCT Rule 4.9(a) the designation of all Contracting States bound by the PCT on the international filing date, for the grant of every kind of protection available and, where applicable, for the grant of both regional and national patents, applicants should always use the latest version of the e-filing software used to generate the request form, or the latest versions of the request form (PCT/RO/101) and demand form (PCT/IPEA/401) (the latest versions are dated 1 July 2020 and 1 July 2019, respectively). The request and demand forms can be printed from the website, in editable PDF format, at: https://www.wipo.int/pct/en/forms/, or obtained from receiving Offices or the International Bureau, or, in the case of the demand form, also from International Preliminary Examining Authorities. Where possible, applicants are encouraged to use ePCT-Filing in order to benefit from the most up-to-date PCT data.